Contact us
Menu
Contact us

Feldan News

Feldan

Feldan

Recent Posts by Feldan:

on Jun 27,2018

Seoul (South Korea) & Québec City (Canada) June 27, 2018 – GC LabCell (hereafter “GCLC”) and Feldan Therapeutics (hereafter “Feldan”) announced an agreement today granting GCLC exclusive rights to use …

Read Story

on Jun 4,2018

Our CEO François-Thomas Michaud and Strategic development director Vincent Menard are pleased to be in Boston this week for the BIO convention. They are looking forward to meeting with international …

Read Story

on May 29,2018

QUEBEC CITY, May 29, 2018 - Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based …

Read Story

on May 1,2018

Feldan Therapeutics’ Research Director, Dr. David Guay, will be attending TIDES: Oligonucleotides and Peptide Therapeutics Conference next week, May 7-10th at Hynes Convention Center in Boston. Come to chat with …

Read Story

on Apr 9,2018

Our CEO Francois-Thomas Michaud and Strategic Alliance Director, Vincent Ménard, MBA Ph.D. will be attending RESI2018 conference in Toronto, April 10th. Come and meet with them to discuss how Feldan …

Read Story

on Apr 5,2018

Read the new article on the Feldan Shuttle Technology published in PLOS One (April 2018) : http://journalsplosorg/plosone/article?id=101371/journalpone0195558 …

Read Story

on Mar 29,2018

QUÉBEC city, March 29, 2018 – CQDM is pleased to announce the selection of a new Quantum Leap project jointly with Feldan Therapeutics for a total amount of $1.2M. The …

Read Story

on Mar 16,2018

Feldan Therapeutics will be attending the Innate Killer Summit from March 27 to 29 in San Diego, CA, USA. Come and meet with our Business Development Director Meriem Benchabane and …

Read Story

on Jan 17,2018

Read the new article on the Feldan Shuttle Technology published in Drug Development & Delivery edition on January 2018. download article : wwwdrug-devcom/Uploads/Public/January%202018%20WEBpdf …

Read Story

on Jan 15,2018

Combined Feldan Shuttle and Green Cross LabCell NK cell technologies will be used to develop hyperactive NK cell immunotherapies QUEBEC, Jan. 15, 2018 /CNW Telbec/ - Green Cross LabCell, involved …

Read Story